Read “Rates of Cortical Atrophy in Adults 80 Years and Older With Superior vs Average Episodic Memory”
Presented, the Fiscal Year 2019 NIH Professional Judgment Budget for Alzheimer’s Disease and Related Dementias. Outlined at the July 28 meeting of the HHS Secretary’s Advisory Council on Alzheimer’s Research, Care, and Services.
The NIA’s Bypass Budget Proposal for Fiscal Year 2018—Stopping Alzheimer’s Disease and Related Dementias: Advancing Our Nation’s Research Agenda is now available
At the direction of Congress, the National Institutes of Health (NIH) develops an annual professional judgment budget to estimate the funds needed to fully pursue scientific opportunities to meet the research goal of the Plan—to effectively treat and prevent Alzheimer’s and related dementias by 2025.
The UC Cures for Alzheimer’s Disease Initiative: A University of California-wide RFA now open for applications.
Sponsored by the UC Office of the President with a foundational grant of $4 million, the UC Cures initiative invited hundreds of laboratories throughout the 10-campus system to find new answers to Alzheimer’s disease and related disorders.
U.S. HHS released the National Plan to Address Alzheimer’s Disease: 2013 Update. The 2013 Update includes a new timeline for achieving its first goal – prevent and effectively treat Alzheimer’s disease by 2025 – and a review of progress over the past year.
The first-ever National Alzheimer’s Plan, initially released in May 2012, was mandated by the bipartisan National Alzheimer’s Project Act (P.L. 111-375), which Congress passed unanimously in 2010. The 2013 Update includes a new timeline for achieving its first goal – prevent and effectively treat Alzheimer’s disease by 2025 – and a review of progress over…
University of South Florida researchers quantify Alzheimer’s and other neuro diseases at $800 billion per year
Read an overview of the substantial current and future economic impact of neurological disease, and an action plan for reducing this burden through neurological research and enhanced clinical management of neurological disorders in the US.
Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited in mild to moderate AD.
“Our results demonstrate that ApoE affects tau pathogenesis, neuroinflammation, and tau-mediated neurodegeneration independently of amyloid-β pathology. ApoE4 exerts a ‘toxic’ gain of function whereas the absence of ApoE is protective” David Holtzman, MD Washington University
When a neuron gets blocked, the delicate harmony that allows the brain to operate seamlessly deteriorates. One result: diseases like Alzheimer’s. Understanding such blockages and how “traffic” should flow normally in healthy brain cells could offer hope to people with neurodegenerative diseases.
Toward that end, a research team led by University at Buffalo biologist Shermali Gunawardena, PhD, has shown that the protein presenilin plays an important role in controlling neuronal traffic on microtubule highways, a novel function that previously was unknown.
By Paul Aisen, M.D. Director, Alzheimer’s Disease Cooperative Study Professor of Neurosciences, University of California San Diego There has been much discussion in the news lately as to whether the amyloid hypothesis is the correct path for research. The amyloid hypothesis is supported by a huge body of evidence, but to my thinking the most…
“Young Latino’s Working in Alzheimer’s” Airs Tonight on UCSD TV and is Streaming on the Brain Channel
Watch a Brain Channel round table about educating, training, mentoring and funding young Latino Alzheimer’s scientists.